Identify the product and its status
The names on the approved labels
At the 28 September 2026 review, the approved tesamorelin labels were for EGRIFTA SV and EGRIFTA WR.
The labels say these versions cannot be swapped for each other.
That review found no approved generic or other approved copy of tesamorelin.
Why “compounded tesamorelin” is a different issue
With compounding, medicine is prepared or mixed in response to an order, rather than supplied as a factory-made product.
Under U.S. rules checked on 26 September 2026, tesamorelin belongs to a group of medicines that pharmacies cannot make to order.
Federal rules do not permit pharmacies to make tesamorelin copies as compounded medicines.
A prescription does not remove that restriction.
A drug code does not prove approval
Online “research” tesamorelin and mixtures with other medicines are not the approved tesamorelin products.
A product’s listing number in government drug records is its National Drug Code, abbreviated NDC.
FDA says that having this number or appearing in its drug records does not prove approval.
The U.S. agency for drugs is the Food and Drug Administration; FDA is its shortened name.
Keep this in mind
A pharmacy-made tesamorelin copy has no lawful route under these compounding rules.